In parallel with the need for surrogate measures in early-phase trials, there are fundamental unanswered questions about the optimal outcome measures to use for phase 3 trials that enroll patients with DoC. Historically, the Glasgow Outcome Scale-Extended (GOSE) [227] has been the outcome measure...
We explore the limitations as well as the potential of blockchain for every intelligent activity separately. Finally, the significant future research direction is solidified to support the growth of smart megacities. Our debate and disquisition are intended to pave the way for further research on ...